Stress fractures in systemic lupus erythematosus after long-term MTX use successfully treated by MTX discontinuation and individualized bone-specific therapy

Lupus. 2019 May;28(6):790-793. doi: 10.1177/0961203319841434. Epub 2019 Apr 4.

Abstract

We report the case of a 64-year-old woman with systemic lupus erythematosus (SLE) and recurrent bilateral stress fractures of the calcaneus due to long-term methotrexate (MTX) use. A detailed skeletal assessment pointed to osteoporomalacia with pronounced trabecular thinning and increased bone resorption. After years of unsuccessful treatment with bisphosphonates, a combined bone-specific denosumab-teriparatide treatment was initiated, and additional belimumab treatment was started to avoid intermittent steroid usage. As these measures did not lead to a significant improvement of the bone situation, MTX was eventually discontinued. This was followed by a rapid clinical improvement. In a follow-up MRI scan after 18 months, the stress fractures had almost disappeared. Furthermore, the bone density and microarchitecture markedly improved. In conclusion, this case demonstrates that MTX discontinuation/replacement in combination with an individualized and state-of-the-art bone-specific therapy is effective in SLE patients with stress fractures after long-term MTX use.

Keywords: Methotrexate; osteoporosis; denosumab; stress fracture; teriparatide.

Publication types

  • Case Reports

MeSH terms

  • Absorptiometry, Photon
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Bone Density / drug effects
  • Bone Density Conservation Agents / therapeutic use
  • Calcaneus / diagnostic imaging
  • Calcaneus / pathology*
  • Diphosphonates / therapeutic use
  • Female
  • Fractures, Stress / chemically induced*
  • Fractures, Stress / diagnostic imaging
  • Humans
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy*
  • Magnetic Resonance Imaging
  • Methotrexate / adverse effects*
  • Methotrexate / therapeutic use
  • Middle Aged

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Bone Density Conservation Agents
  • Diphosphonates
  • belimumab
  • Methotrexate